|
Antidepressants
effectiveness
adults:
In
this
group
of
studies
the
best
results
found
revealed
drug
result
were
13%
better
than
a
sugar
pill
meaning
that
87%
of
patient
can
expect
results
no
better
than
taking
a
sugar
pills.
In
review
of a
significant
number
of
placebo
controlled
double
blind
studies
most
reveal
depression
treatment
results
no
better
than
a
sugar
pill
in
adults.
The
following
are
studies
of
reuptake
inhibitor
antidepressants
in
adults.
Full text
adult study
1
study 1:
Literature review, N = 1,472. Conclusions: Remission rates (of
depression) for the serotonin reuptake inhibitor when
used in depression
escitalopram (Lexapro) were
superior to placebo (48.7% versus 37.6%, P =0.003)
88.8% of people suffering with depression taking Lexapro achieved results
no better than placebo. Remission rates (of
depression) for serotonin reuptake inhibitor depression citalopram (Celexa) (52.8% versus
43.5%, P = 0.003). 90.7% of people suffering with
depression taking Celexa
achieved results no better than placebo. Depression
remission
rates for escitalopram (Lexapro) were .. similar
to the serotonin norepinephrine reuptake inhibitor venlafaxine-XR (Effexor-XR) (P= 0.97).
Full text
adult study
2
study 2:
Randomized double blind placebo controlled 20 month
depression study on the incidence of recurrence of depression.
Three groups serotonin depression reuptake inhibitor Zoloft (sertraline) 50 mg per
day versus serotonin depression reuptake inhibitor Zoloft (sertraline)
100 mg per day versus placebo. The depression subjects mean age 45.2 years with a
standard deviation of 10.5 years, N = 299.
Conclusion: "..a new depression episode was
recorded in 33.3% of people suffering with depression in the placebo group and
in 16.9% of those who received serotonin depression reuptake
inhibitor sertraline (Table
2). No statistically significant difference was observed
in the incidence of depression recurrence between the 50-mg
sertraline group and the 100-mg sertraline group (16.8%
and 17.0%." 87% of people suffering with
depression taking serotonin
depression reuptake inhibitor Zoloft at
50 mg per day or 100 mg per day received depression benefits
no better than placebo in prevention of recurrent
depression.
Full text
adult study
3
study 3:
Randomized double blind placebo controlled 8 week
depression study
of chronic fatigue syndrome in people with depression
using serotonin depression reuptake inhibitor Prozac
versus placebo average age of the depression subjects about 39
years, N = 96. Conclusions: No
significant difference between serotonin depression reuptake
inhibitor Prozac or placebo
in the treatment of chronic fatigue syndrome or
associated depression.
Full text
adult study
4
study 4:
Randomized placebo controlled double blind depression study of
serotonin depression reuptake inhibitor
Prozac (fluoxetine) versus depression counseling versus
placebo in the treatment of post-partum depression
average age about 26 years old, N = 86.
Conclusion: No difference in the effectiveness
of depression counseling versus serotonin depression reuptake inhibitor Prozac. No benefit from combining
depression counseling with Prozac. Depression counseling is just as
effective as serotonin depression reuptake inhibitor Prozac treatment under these conditions,
without the side effects.
Full text
adult study
5
study 5: Randomized
double blind placebo controlled 12 week depression study with the
treatment of adult depression serotonin depression reuptake
inhibitor Prozac (fluoxetine)
versus serotonin reuptake inhibitor Paxil (paroxetine) versus placebo
mean age 41.3 years (SD 12.6), N = 128. Conclusion:
"There were no significant differences among the three
depression treatment groups in baseline depression and endpoint depression and
anxiety severity, as well as in the degree of depression
and anxiety improvement."
Full text
adult study
6
study 6: Randomized
double blind placebo controlled 3 way depression study of serotonin
depression reuptake inhibitor Prozac
(fluoxetine) versus serotonin norepinephrine
depression reuptake inhibitor Effexor (Venlafaxine)
versus placebo in the treatment of depression with
adults over 18 years of age, N = 308. Conclusion:
"Final depression remission (defined as HAM-D < or =7) rates were
32%, 28%, and 22% for serotonin norepinephrine
depression reuptake
inhibitor venlafaxine, serotonin depression reuptake
inhibitor fluoxetine, and
placebo, respectively." Depression treatment
under the approach of this study shows that 90% of
people suffering with depression treated with
serotonin norepinephrine depression reuptake inhibitor
Effexor have depression results no better than
placebo, and 94% of people suffering with depression treated with serotonin depression reuptake inhibitor Prozac have results no
better than placebo.
Antidepressants
effectiveness
adults |
